5 completed, 4 terminated, 2 recruiting, 1 active not recruiting. 8 Phase 2, 5 Phase 1, 2 Early Phase 1, 1 Not applicable.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 8 | Completed 3, Terminated 3, Active not recruiting 1, Not yet recruiting 1 |
| Phase 1 | 5 | Completed 3, Terminated 2 |
| Early Phase 1 | 2 | Recruiting 2 |
| Not applicable | 1 | Completed 1 |
Follow Non-Hodgkin Lymphoma (NHL): new trials by email Literature Review of Non-Hodgkin Lymphoma (NHL) trials Research Report on Non-Hodgkin Lymphoma (NHL)
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| BAFF CAR-T Cells (LMY-920) for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma and Multiple Myeloma BAFF CAR-T - Non-Hodgkin Lymphoma Refractory/ Relapsed, Multiple Myeloma Refractory | Phase 2 | Not yet recruiting | Luminary Therapeutics | 90 | 2026-12-01 | 2026-08-18 |
| Clinical Study of LV009 Injection for the Treatment of Relapsed/Refractory CD19-Positive Hematologic and Lymphoid Malignancies LV009 Injection Infusion - Non-Hodgkin Lymphoma (NHL), Acute Lymphoblastic Leukemia (ALL), Adult | Early Phase 1 | Recruiting | PersonGen BioTherapeutics (Suzhou) Co., Ltd. | 19 | 2025-09-25 | 2025-12-31 |
| An Open-label, Single-arm Clinical Study to Evaluate the Safety and Preliminary Efficacy of OriV508 Injection in Treating Relapsed/Refractory Hematological Malignancies OriV508 Injection - Multiple Myeloma (MM), Non-Hodgkin Lymphoma (NHL) | Early Phase 1 | Recruiting | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | 40 | 2025-09-08 | 2026-07-21 |
| VOB560-MIK665 Combination First in Human Trial in Patients With Hematological Malignancies (Relapsed/Refractory Non-Hodgkin Lymphoma, Relapsed/Refractory Acute Myeloid Leukemia, or Relapsed/Refractory Multiple Myeloma) VOB560, MIK665 - Non-Hodgkin Lymphoma (NHL), Acute Myeloid Leukemia (AML) | Phase 1 | Terminated | Novartis Pharmaceuticals | 37 | 2021-06-23 | 2025-10-10 |
| Effects of Itraconazole and Rifampin on the Blood Tazemetostat Levels Tazemetostat, Itraconazole, Rifampin - All Malignancies, Advanced Malignancies | Phase 1 | Completed | Epizyme, Inc. | 42 | 2020-04-23 | 2025-02-19 |
| A Study to Assess Long-term Safety of Tazemetostat in Adult Participants of All Ages With Any Disease Treated With Tazemetostat in a Previous Clinical Study Tazemetostat - Diffuse Large B-cell Lymphoma (DLBCL), Follicular Lymphoma (FL) | Phase 1 / Phase 2 | Completed | Epizyme, Inc. | 58 | 2016-08-30 | 2025-11-04 |
| Provision of TCRγδ T Cells and Memory T Cells Plus Selected Use of Blinatumomab in Naïve T-cell Depleted Haploidentical Donor Hematopoietic Cell Transplantation for Hematologic Malignancies Relapsed or Refractory Despite Prior Transplantation Anti-thymocyte globulin (rabbit), Blinatumomab, Cyclophosphamide - Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia (AML) | Phase 2 | Active not recruiting | St. Jude Children's Research Hospital | 170 | 2016-07-14 | 2025-08-12 |
| Repeat Transplantation for Relapsed or Refractory Hematologic Malignancies Following Prior Transplantation Cyclophosphamide, Fludarabine, G-CSF - Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia (AML) | Phase 2 | Terminated | St. Jude Children's Research Hospital | 12 | 2014-10-01 | 2017-05-30 |
| Study Evaluating Venetoclax in Subjects With Hematological Malignancies azacitadine, venetoclax, rituximab / IDEC-C2B8 - Non-Hodgkin Lymphoma (NHL), Multiple Myeloma (MM) | Phase 1 / Phase 2 | Completed | AbbVie | 38 | 2014-09-22 | 2021-08-02 |
| Response to Influenza Vaccination in Lymphoma Patients Treated With Rituximab influenza vaccination with influenza vaccine - Non-Hodgkin Lymphoma (NHL) | Not applicable | Completed | St. Antonius Hospital | 98 | 2012-10-01 | 2014-01-31 |
| Brentuximab Vedotin (SGN-35) in Patients With Mycosis Fungoides With Variable CD30 Expression Level Brentuximab vedotin - Non-Hodgkin Lymphoma (NHL), Cutaneous Lymphoma | Phase 2 | Completed | Youn Kim | 36 | 2011-05-01 | 2017-04-05 |
| Haploidentical Allogeneic Transplant With Post-transplant Infusion of Regulatory T-cells Regulatory T-cells, Conventional T-cells, Melphalan - Leukemia, Acute, Chronic Myelogenous Leukemia (CML) | Phase 1 / Phase 2 | Terminated | Everett Meyer | 10 | 2009-06-01 | 2018-06-27 |
| Sirolimus & Mycophenolate Mofetil as GvHD Prophylaxis in Myeloablative, Matched Related Donor HCT Sirolimus, Mycophenolate mofetil (MMF), Carmustine - Hematologic Diseases, Acute-graft-versus-host Disease | Phase 2 | Terminated | Stanford University | 3 | 2006-08-01 | 2017-06-05 |
Lymphoma, Non-Hodgkin (13) · Leukemia, Myeloid, Acute (5) · Multiple Myeloma (4) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (4) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (3) · Myelodysplastic Syndromes (3) · Hematologic Neoplasms (2) · Leukemia (2) · Leukemia, Lymphocytic, Chronic, B-Cell (2) · Leukemia, Myelomonocytic, Juvenile (2) · Lymphoma, Follicular (2) · Lymphoma, Large B-Cell, Diffuse (2) · Mesothelioma (2) · Sarcoma, Myeloid (2) · Sarcoma, Synovial (2)
Hemic and Lymphatic Diseases (13) · Immune System Diseases (13) · Immunoproliferative Disorders (13) · Neoplasms by Histologic Type (13) · Lymphatic Diseases (12) · Lymphoma (12) · Lymphoproliferative Disorders (12) · Neoplasms (12) · Hematologic Diseases (9) · Disease Attributes (5) · Leukemia (5) · Leukemia, Lymphoid (5) · Leukemia, Myeloid (5) · Pathologic Processes (5) · Pathological Conditions, Signs and Symptoms (5)
Cyclophosphamide (3) · Melphalan (3) · Rituximab (3) · Thiotepa (3) · Antilymphocyte Serum (2) · Filgrastim (2) · Granulocyte Colony-Stimulating Factor (2) · Sirolimus (2) · fludarabine (2) · fludarabine phosphate (2) · tazemetostat (2) · thymoglobulin (2) · Brentuximab Vedotin (1) · Carmustine (1) · Etoposide (1)
Epizyme, Inc. (2) · St. Jude Children's Research Hospital (2) · AbbVie (1) · Everett Meyer (1) · Luminary Therapeutics (1) · Novartis Pharmaceuticals (1) · PersonGen BioTherapeutics (Suzhou) Co., Ltd. (1) · St. Antonius Hospital (1) · Stanford University (1) · Union Hospital, Tongji Medical College, Huazhong University of Science and Technology (1) · Youn Kim (1)
United States (8) · Belgium (2) · China (2) · Japan (2) · Spain (2) · Australia (1) · Finland (1) · France (1) · Hong Kong (1) · Israel (1) · Italy (1) · Netherlands (1) · Poland (1) · South Korea (1) · Ukraine (1)
Brandon Triplett, MD (2) · Everett H Meyer, MD, PhD (1) · Heng Mei, Ph.D&M.D (1) · Laura Johnston (1) · Minke AE Rab, Drs. (1) · Youn H Kim (1)
2015 (1), 2023 (1)